Taipei City Psychiatric Center, Taipei City Hospital
Taipei, 110, Taiwan
NCT Number: NCT00628017
This preliminary study is aimed to investigate whether it is feasible to conduct a study to use fish oil compared to the placebo(olive oil) in people with cognitive impairment. We will also explore whether fish oil has better efficacy in some clinical aspects in people with cognitive impairment during 24 weeks intervention. The major clinical outcome will be:
1. general clinical impression 2. cognitive function
Looking for future studies?
Notify Me55 year–90 year
All sexes
Interventional
Not applicable
Taipei, 110, Taiwan
Despite some positive findings from observational and animal studies, the effects of n-3 PUFA administration on cognitive impairment in humans have received little evaluation to date. Although some clinical trials of fish oil have been reported, the results are inconsistent. Given these inconsistent findings, we carried out a preliminary study to investigate the effect of fish oil monotherapy on cognitive function and general clinical condition in patients with cognitive impairment.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
Other names: fish oil, n3 fatty acids
Time frame: 24 weeks
Time frame: 24 weeks
Time frame: 24 weeks
Time frame: 24 weeks
Time frame: 24 weeks
Taipei City Psychiatric Center, Taiwan
Other
The Effects of Omega-3 Fatty Acids Monotherapy in Alzheimer's Disease and Mild Cognitive Impairment: a Preliminary Randomized Double-Blind Placebo-Controlled Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04073628
Alzheimer Disease, Alzheimer's Disease
Albany, New York, United States
View Trial DetailsNCT00647478
Alzheimer Disease, Alzheimer's Disease
Paris, France
View Trial DetailsNCT06595030
Alzheimer Disease, Alzheimer's Disease
Menands, New York, United States
View Trial DetailsNCT04426539
Alzheimer Disease, Alzheimer's Disease
Philadelphia, Pennsylvania, United States
View Trial Details